Seelos Therapeutics to Participate in The Benchmark Company Healthcare Conference
NEW YORK, May 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on Wednesday, May 26, 2021.
Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls.
Additional information about the conference may be accessed here.
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-benchmark-company-healthcare-conference-301296611.html
SOURCE Seelos Therapeutics, Inc.
Company Codes: NASDAQ-NMS:SEEL